Develops and manufactures specialty additives for various industries. Provides nutrition and care products for consumer goods, animal nutrition, and healthcare. Now — the numbers.
This is an established company with proven profits.
No real growth (-2% a year). Red columns mark years that ended in a loss.
The gap is $3.8B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 34× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
The stock trades 33% below its peak. The market has trimmed its expectations for the company.
It pays out $1.15 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 2% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 34 times its annual profit. Even a small disappointment could hit the price hard.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.